The effect of long-term statin use on diabetic nephropathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Gut microbiota may mediate the causality of statins on diabetic nephropathy: a mediation Mendelian randomization study.International urology and nephrology · 2025 · on this map
   Observational
2. A Network Pharmacology-Based Investigation into the Mechanism of Quercetin Combined with Rosuvastatin in Delaying Diabetic Nephropathy via Inhibiting NRK-52E Cell Ferroptosis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
   Article
3. The association between statin use and diabetic nephropathy in US adults: data from NHANES 2005 - 2018.Frontiers in endocrinology · 2024
   Article

Corrections and comments

• Comment on
  Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice.2023

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as